Maxigen Biotech Inc. (1783.TW) Stock

About Maxigen Biotech Inc.

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic viscoelastic under the PreviscAid, ViscAid, and BiVisc brands; intra-articular injections under the ArtiBest and ArtiAid brands; synthetic bone grafts under the BestAid, GingivAid, FormaGraft, and Foramic brands; and dermal filler injections under the Formaderm brand. In addition, the company provides collagen based regenerative matrixes comprising HealiAid, a collagen wound dressing; NasoAid, an intranasal splint; and FormaAid, a collagen membrane. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.

Maxigen Biotech Inc. is led by CEO Ching-Ting Chen, employs 127 people, headquartered in Taoyuan City, TW, publicly traded since 2012.

Maxigen Biotech Inc. (1783.TW) stock trades at $38.10 with a market capitalization of $3.42B. The stock is valued at a price-to-earnings (P/E) ratio of 11.80, price-to-book of 2.28, price-to-sales of 4.08. Over the past 52 weeks the stock has ranged between $36.10 and $48.30, and currently trades 21.1% below its 52-week high. It pays a dividend yielding 5.25%.

On profitability, Maxigen Biotech Inc. generates a return on equity (ROE) of 20.00%, above the typical market range of roughly 12-15%, an operating margin of 25.69%, a net profit margin of 34.77%.

Official website: mbi-bio.com

Maxigen Biotech Inc. (1783.TW) — frequently asked questions